FDA Accepts SNY and REGN's Dupixent Re-Submitted sBLA for Urticaria
The FDA is set to give its decision on SNY and REGN's sBLA for Dupixent for chronic spontaneous urticaria on April 18, 2025.
'Staggeringly high' discontinuation rates for GLP-1 drugs like Ozempic or Wegovy
The use of diabetes and weight-loss medications like Ozempic or Wegovy—called GLP-1 drugs—has exploded in recent years, with ...
A new discovery about pain signaling may contribute to better treatment of chronic pain
When pain signals are passed along the nervous system, proteins called calcium channels play a key role. Researchers at ...
Pharmabiz20h
US FDA accepts for review the resubmission of sBLA for Dupixent to treat chronic spontaneous urticaria
US FDA accepts for review the resubmission of sBLA for Dupixent to treat chronic spontaneous urticaria: Paris Monday, November 18, 2024, 11:00 Hrs [IST] The US Food and Drug Admin ...